5 results about "Sindbis virus" patented technology

Embodiments of the invention disclosed herein involve the selective engineering of Sindbis virus so as to generate cells that make enveloped virus-like particles that contain therapeutic mRNAs, and whose membrane proteins have been mutated to serve as modular binding sites for cell-targeting ligands.

The present invention relates to compounds for use in the treatment of a disease or condition caused by Zika virus, Dengue virus, West Nile virus, Chikungunya virus, O`nyong`nyong virus, Sindbis virus or SARS-CoV-2 virus.

The application discloses a multiplex qPCR primer probe set, a kit, a detection method and application for detecting alphaviruses, and belongs to the technical field of molecular biological detection. The application designs a set of primer probe combination for a plurality of alphaviruses capable of infecting insect cell lines, including western equine encephalitis virus, eastern equine encephalitis virus, sindbis virus, chikungunya virus, AURA virus and Venezuelan equine encephalitis virus. The combination realizes synchronous detection and identification of a plurality of target viruses in one reaction system. The application also provides a kit containing the primer probe set and a corresponding detection method. The detection method has the advantages of wide coverage, high detection sensitivity, strong specificity, good anti-matrix interference capability and the like, and is suitable for safety detection and quality control of alphavirus contamination in insect cell banks, cell cultures and related biological products.

The application discloses a non-neurotoxic VSV vector recombinant oncolytic virus carrying a Sindbis virus G protein, and is a self-replicating recombinant oncolytic virus VSV-SING which is obtained by replacing the G protein coding gene of a wild type VSV with the G protein coding gene of a Sindbis virus through reverse genetic manipulation technology, and has non-neurotoxicity and high oncolytic activity.

Macrophages (Mφ) are crucial for pathogen detection and elimination, and also serve as a microenvironment for replication of multiple infectious pathogens. This delicate balance between viral replication and antiviral response remains largely unknown at the molecular level. Addressing this issue is physiologically important given the persistent threat posed by emerging viral pathogens. Here, we demonstrate that GAS7 expression within macrophages restricts the replication of viral pathogens belonging to all major viral groups. We show that the antiviral activity of GAS7 exists even under conditions where the classical antiviral response mediated by type I interferon is neutralized. In particular, we show that in human monocyte-derived macrophages, silencing of GAS7 boosts the replication of multiple viral pathogens representing most relevant viral groups. These include the retroviruses HIV-1 (human immunodeficiency virus type 1) and HIV-2 (human immunodeficiency virus type 2), the RNA viruses Zika virus (positive-sense single-stranded RNA), Sindbis virus (single-stranded positive-sense RNA), Sendai virus (negative-sense single-stranded RNA), VSV virus (negative-sense single-stranded RNA), and measles virus (negative-sense single-stranded RNA), and the DNA virus HSV-1 virus (double-stranded DNA). Importantly, the antiviral activity of GAS7 is present even under conditions where type I interferon is neutralized by the addition of the B18R protein (which efficiently blocks the type I receptor). Furthermore, the inventors demonstrate that by forcing macrophages to overexpress GAS7, they are further protected from HIV-1 infection compared to cells expressing this factor at normal levels. Therefore, the present invention relates to the modulation of GAS7 expression and / or activity for modulating viral replication in macrophage populations.